HomeAI · summaries
Storia in 3 fonti
Exelixis Stock Slips as FDA Delays Cancer Drug Review - Exelixis (NASDAQ:EXEL)
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
investors.com
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug
Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer combo.
- ·
endpoints.news
FDA extends review of Exelixis' colorectal cancer drug candidate
FDA extends review of Exelixis' zanzalintinib-Tecentriq combo in mCRC by three months to March 3 after new data submission.
